Glen Harbor Capital Management’s Emergent Biosolutions EBS Stock Holding History

Glen Harbor Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$376K	Buy	7,196 +560	+8%	+$26.1K	0.01%	807
2019 Q2	$321K	Buy	6,636 +84	+1%	+$4.03K	0.01%	863
2019 Q1	$331K	Hold	6,552	–	–	0.01%	833
2018 Q4	$388K	Buy	6,552 +28	+0.4%	+$1.8K	0.01%	711
2018 Q3	$429K	Buy	6,524 +28	+0.4%	+$1.63K	0.01%	781
2018 Q2	$328K	Hold	6,496	–	–	0.01%	805
2018 Q1	$342K	Buy	6,496 +812	+14%	+$40.5K	0.01%	777
2017 Q4	$264K	Buy	5,684 +980	+21%	+$41.3K	0.01%	883
2017 Q3	$190K	Buy	4,704 +1,316	+39%	+$47.6K	﹤0.01%	925
2017 Q2	$115K	Buy	3,388 +1,708	+102%	+$52.7K	﹤0.01%	1049
2017 Q1	$49K	Sell	1,680 -1,624	-49%	-$49.4K	﹤0.01%	1128
2016 Q4	$109K	Buy	+3,304	New	+$99.1K	﹤0.01%	879

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glen Harbor Capital Management's EBS Position: Q3 2019 in Review

Glen Harbor Capital Management increased its Emergent Biosolutions (EBS) stake by 8.4% in Q3 2019, buying an estimated $26.1K and bringing the position to 7,196 shares worth $376K. The position accounts for 0.01% of the portfolio, ranked #807.

Glen Harbor Capital Management first reported a position in EBS in Q4 2016 and has held it in 12 quarters since. The position peaked at $429K in Q3 2018. 244 funds tracked by Wall St. Rank hold EBS as of Q3 2019.

Glen Harbor Capital Management held 7,196 shares of Emergent Biosolutions worth $376K as of Q3 2019.
Glen Harbor Capital Management bought 560 Emergent Biosolutions shares in Q3 2019, an estimated $26.1K.
Emergent Biosolutions made up 0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #807 holding.
Glen Harbor Capital Management first reported a position in Emergent Biosolutions in Q4 2016 and has held it in 12 quarters since.
Glen Harbor Capital Management's Emergent Biosolutions position peaked at $429K in Q3 2018.
244 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.